Cibinqo
(Abrocitinib)ApprovedSmall molecule
PfizerAbrocitinib is used to treat moderate to severe atopic dermatitis (eczema), a skin condition that causes itching, inflammation, and irritation. It helps reduce these symptoms by calming down the immune system's overactive response in the skin.[2] Cibinqo is currently approved and in use across 12 indications[4].[1]
Cibinqo is one of 313 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Approved.
12
Indications
31
Total Trials
18
Active Trials
312
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
126 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Cibinqo
PfizerApproved
Rituxan
RochePhase 3
Medrol
PfizerPhase 3
Rinvoq
AbbViePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Gazyva
RochePhase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Fludara
SanofiPhase 2
Glucocorticoid
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis15 trials
Show 12 more trials
Maintenance of Optimal Disease Control During Abrocitinib Dose Tapering in Patients With Atopic Dermatitis
Not yet recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Approved·NCT07848074·100 enrolled
Oral1 trial
Prurigo Nodularis1 trial
12 more indications
Caffeine1 trial
Toxic Epidermal Necrolysis1 trial
Fatigue1 trial
Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID
Active, not recruiting·—·Phase 2·NCT06597396·46 enrolled
Pregnant Women and Their Offspring1 trial
Efficacy and Safety1 trial
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT06573593·150 enrolled
Dermatitis, Atopic1 trial
Granuloma Annulare1 trial
Eczema1 trial
Diabetes Mellitus, Type 11 trial
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subtype-Selective JAK Inhibitors for Preservation of Pancreatic β Cell Function in Newly Diagnosed Type 1 Diabetes Mellitus
Active, not recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT05743244·78 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 14, 2022
CIBINQO
NDA NDA213871
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Cibinqo drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Abrocitinib. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]